Amgen

Open: 224.16 Close: 222.61 Change: -1.55

16 risks of investing in Amgen Stock found by an AI after reading the whole internet.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, announce, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen closed at $227.11, marking a -1.11% move from the previous day. Amgen is projected to report earnings of $4.46 per share, which would represent a 4.09% drop in real profit. California Attorney General Rob Bonta said Amgens proposed acquisition of Horizon is dangerous.

Today's News

Amgen Inc. per Employee $1.029M P/E Ratio 15.13 P/P ratio 15.71 Yield 3.83% Dividend $2.13 Ex-Dividend May 17, 2023 short interest 7.2M 06/15/23 % of Float Shorted 1.35% Average Volume 2.37M. Amgen announced a 60% cut in price on October 26, 2018 the maker of the drug, Amgen, announced a $5,850 per year price cut. Amgen is the worlds largest biotechnology firm. Amgen announced plans to buy Horizon in December, saying its rare disease drugs would offer it some protection from the drug pricing provisions of the Inflation Reduction Act. California Attorney General Rob Bonta said Amgens proposed acquisition of Horizon is dangerous for the future of medicine. Amgen Inc. v. Sanofi Inc. clarifying the enabling obligation of the patent act: Amgen inc.v. sanofi - Patent - United States Home USA. Amgen announced plans to buy Horizon Therapeutics in December. Amgen said its rare disease drugs would offer it some protection from drug pricing provisions of the Inflation Reduction Act. Amgen (AMGN) Dips More Than Broader Markets: What You Should Know Zacks. Amgen (AMGN) Dips More Than Broader Markets: What You Should Know - June 23, 2023 - Zacks.com. In the latest trading session, Amgen closed at $227.11, marking a -1.11% move from the previous day. Amgen is projected to report earnings of $4.46 per share, which would represent a 4.09% drop in real profit Beast Signal Filipivated 29 newspaper purchasingciating Requ Guest laptopChall Amgen is advancing more than a dozen BiTE molecules across a broad range of hematologic malignancies and solid tumors. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T cell treatment available to all providers when their patients need it. Amgen was established in Thousand Oaks, California, in 1980. Founded in 1983, Amgen went public on June 17, 1983, raising $40 million. Amgen received approval for the first recombinant human erythropoetin product, Epogen in 1989. Amgen was ranked 123 on the Fortune 500 list of the largest U.S. corporations by revenue. Amgen acquired Onyx Pharmaceuticals in October 2013. In November, construction was completed on Amgens next-generation biomanufacturing facility. Amgen History official site page accessed January 2, 2016. Amgen, AT&T, Others Announce Commitments for COVID-19 Response The intrinsic value of one Amgen stock under the Base Case scenario is 199.4 USD. Compared to the current market price of 222.85 USD , Amgen Inc is Overvalued by 11%. The higher the solvency score, the more solvent the company is. Amgen to present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. Amgen and TScan Therapeutics announce multi-year collaboration that will use TScans proprietary target discovery platform.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, announce, drug, Inc, price, Horizon, say, and the most common words in the summary are: amgen, drug, year, market, inc, price, stock, . One of the sentences in the summary was: California Attorney General Rob Bonta said Amgens proposed acquisition of Horizon is dangerous.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #drug #year #market #inc #price #stock.